Acrux Limited (ACR:ASX) | ACN 082 001 152 103-113 Stanley St, West Melbourne VIC, 3003 Australia +61 3 8379 0100 | info@acrux.com.au Acrux Limited (ACR:ASX) ASX Announcement 19 October 2026 Quarterly Activities Report and Appendix 4C – September Quarter 2026 Highlights: • Acrux...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 8 pages · English
Release
Story so far
Earlier from Acrux
- FDA clears regulatory pathway for Female Testosterone MDTS
- Acrux has received $1.977m RDTI rebate for FY26
- FY26 Annual Report and Appendix 4E
- Investor Presentation - Female Testosterone for HSDD
- Update - Licensing Lenzetto for Australia for AUD5.4m
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux